Unidad de Investigación Clínica en Inmunoterapia del Cáncer H12O-CNIO

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica en Inmunoterapia del Cáncer H12O-CNIO

Luis Álvarez-Vallina
Luis Álvarez-Vallina Jefe de Unidad de Investigación Clínica
T +34 (+34) 917 328 000 (Ext )


  • Belén Blanco
  • Anais Jiménez

Becarios Post-doctorales

  • Rodrigo Lázaro
  • Ángel Ramírez
  • Antonio Tapia
  • Ivana Zagorac

Becarios Pre-Doctorales

  • Francisco Javier Arroyo
  • Laura Díez
  • Carmen Domínguez
  • Marina Gómez
  • Laura Rubio
  • Alejandro Segura
  • Miriam Velasco

Técnicos de Laboratorio

  • María de la Yedra Pacheco

Immunotherapy has opened a new era in cancer treatment. Our Unit focuses on understanding the molecular and cellular mechanisms of cancer immune escape for designing next-generation cancer immunotherapies. For example, we have developed a novel cancer immunotherapy strategy based on the secretion of bispecific T cell-engaging (TCE) antibodies by engineered human T (STAb-T) cells, which has been shown to be effective in solid and hematological malignancies and is currently in clinical trial. The Cancer Immunotherapy Clinical Research Unit has several research areas of interest: 1) reactivation (rescue) of pre-existing tumor-specific endogenous T cell repertoires(e.g., tumor-infiltrating lymphocytes), 2) development of T cell redirecting strategies to improve the clinical efficacy and safety profile of tumor-reactive artificial T cells, and 3) development of multi-targeting approaches recognizing tumor-associated antigens (TAA) and/or tumor-specific antigens (TSA) at both extra- and intracellular locations. Moreover, our group has a strong interest in the generation of multivalent and multispecific antibody formats and the use of engineered mRNA-based gene delivery systems. Finally, our Unit has a firm commitment to introduce new immuno-oncology drugs and adoptive cell therapies in the clinic, to provide high-quality personalized treatments.